Literature DB >> 7044068

Structure and function of mucus.

A Silberberg, F A Meyer.   

Abstract

Discussing the available evidence a fairly strong case can be made for the existence of a basic glycoprotein unit, characterized by what may be a common protein backbone (Fig. 1). This is far less likely for the carbohydrate portion. The considerably more variability in the amount and composition of the carbohydrate coat and species and organ differences may arise because of this fact. Very large aggregates are built up from the basic unit using cross-links of disulfide bonds either intermolecularly, i.e. directly, or intramolecularly, i.e. indirectly via a possible lectin-like structure which forms its bond with some of the carbohydrate side chains. Structures of the order of 10-100 million molecular weight are to be expected which, being heavily entangled, give rise to the special rheological character of the mucus. In most instances mucus behaves rheologically like a gel. The concentration of glycoprotein in the mucus may be the most important parameter which determines the special rheological features required in a special functional context. A unified point of view, when discussing mucus structure and function, was taken. On the evidence available, it seems well justified to continue to do so.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7044068     DOI: 10.1007/978-1-4615-9254-9_6

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  10 in total

1.  Colorectal delivery and retention of PEG-Amprenavir-Bac7 nanoconjugates--proof of concept for HIV mucosal pre-exposure prophylaxis.

Authors:  Mahta Samizadeh; Xiaoping Zhang; Simi Gunaseelan; Antoinette G Nelson; Matthew S Palombo; Daniel R Myers; Yashveer Singh; Usha Ganapathi; Zoltan Szekely; Patrick J Sinko
Journal:  Drug Deliv Transl Res       Date:  2016-02       Impact factor: 4.617

2.  Human colonic goblet cells. Demonstration of distinct subpopulations defined by mucin-specific monoclonal antibodies.

Authors:  D K Podolsky; D A Fournier; K E Lynch
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

3.  Viruses and the origin of microbiome selection and immunity.

Authors:  Steven D Quistad; Juris A Grasis; Jeremy J Barr; Forest L Rohwer
Journal:  ISME J       Date:  2016-12-16       Impact factor: 10.302

4.  Composition of human colonic mucin. Selective alteration in inflammatory bowel disease.

Authors:  D K Podolsky; K J Isselbacher
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

5.  Diffusivity of bile salt/phospholipid aggregates in mucin.

Authors:  C Y Li; C L Zimmerman; T S Wiedmann
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

6.  Mucin degradation in human colon ecosystems. Isolation and properties of fecal strains that degrade ABH blood group antigens and oligosaccharides from mucin glycoproteins.

Authors:  L C Hoskins; M Agustines; W B McKee; E T Boulding; M Kriaris; G Niedermeyer
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

7.  Entamoeba histolytica trophozoites in the lumen and mucus blanket of rat colons studied in vivo.

Authors:  G J Leitch; A D Dickey; I A Udezulu; G B Bailey
Journal:  Infect Immun       Date:  1985-01       Impact factor: 3.441

8.  Rat intestinal mucosal responses to a microbial flora and different diets.

Authors:  R Sharma; U Schumacher; V Ronaasen; M Coates
Journal:  Gut       Date:  1995-02       Impact factor: 23.059

9.  A membrane-associated neuraminidase in Entamoeba histolytica trophozoites.

Authors:  I A Udezulu; G J Leitch
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

10.  A biophysical basis for mucus solids concentration as a candidate biomarker for airways disease.

Authors:  David B Hill; Paula A Vasquez; John Mellnik; Scott A McKinley; Aaron Vose; Frank Mu; Ashley G Henderson; Scott H Donaldson; Neil E Alexis; Richard C Boucher; M Gregory Forest
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.